AKUMS DRUGS & PHARMACEUTICALS
|
AKUMS DRUGS & PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 16.67 | 22.09 | -0.28 | 6.63 | -35.30 |
| CEPS(Rs) | 26.84 | 32.48 | 8.84 | 14.72 | -10.92 |
| DPS(Rs) | 3.00 | - | - | - | - |
| Book NAV/Share(Rs) | 216.41 | 199.01 | 49.59 | 50.13 | 86.95 |
| Tax Rate(%) | 32.90 | 0.43 | 101.74 | 34.92 | -29.85 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 11.98 | 11.18 | 2.94 | 8.04 | -2.50 |
| EBIT Margin(%) | 10.92 | 9.22 | 0.13 | 5.38 | -4.81 |
| Pre Tax Margin(%) | 8.77 | 8.38 | -1.08 | 4.11 | -5.26 |
| PAT Margin (%) | 5.88 | 8.35 | 0.02 | 2.68 | -6.83 |
| Cash Profit Margin (%) | 9.43 | 12.07 | 3.03 | 5.76 | -4.25 |
| Performance Ratios | |||||
| ROA(%) | 5.59 | 9.42 | 0.02 | 3.11 | -9.64 |
| ROE(%) | 8.06 | 18.30 | 0.11 | 14.61 | -33.30 |
| ROCE(%) | 14.77 | 17.83 | 0.43 | 17.59 | -18.00 |
| Asset Turnover(x) | 0.95 | 1.13 | 1.26 | 1.16 | 1.41 |
| Sales/Fixed Asset(x) | 1.86 | 1.99 | 2.32 | 2.24 | 2.56 |
| Working Capital/Sales(x) | 1.77 | 2.98 | 5.72 | 5.96 | 6.21 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.54 | 0.50 | 0.43 | 0.45 | 0.39 |
| Receivable days | 65.60 | 71.09 | 73.33 | 86.36 | 70.36 |
| Inventory Days | 60.15 | 58.11 | 59.41 | 72.52 | 57.27 |
| Payable days | 90.39 | 88.12 | 78.67 | 92.84 | 72.46 |
| Valuation Parameters | |||||
| PER(x) | 27.96 | 21.49 | - | - | - |
| PCE(x) | 17.36 | 14.61 | - | - | - |
| Price/Book(x) | 2.15 | 2.38 | - | - | - |
| Yield(%) | 0.64 | - | - | - | - |
| EV/Net Sales(x) | 1.27 | 1.63 | 0.06 | 0.11 | 0.07 |
| EV/Core EBITDA(x) | 8.49 | 12.98 | 1.55 | 1.08 | -3.90 |
| EV/EBIT(x) | 11.61 | 17.65 | 45.56 | 2.11 | -1.53 |
| EV/CE(x) | 1.63 | 2.19 | 0.20 | 0.33 | 0.27 |
| M Cap / Sales | 1.64 | 1.76 | - | - | - |
| Growth Ratio | |||||
| Net Sales Growth(%) | 5.85 | -1.44 | 14.32 | -0.46 | 34.87 |
| Core EBITDA Growth(%) | 25.97 | 229.02 | -59.12 | 655.88 | -122.12 |
| EBIT Growth(%) | 25.36 | 7,018.68 | -97.29 | 211.33 | -198.62 |
| PAT Growth(%) | -25.42 | - | -99.19 | 138.99 | -303.24 |
| EPS Growth(%) | -24.54 | 7,932.55 | -104.25 | 118.78 | -103.74 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.02 | - | 0.69 | 0.75 | 0.58 |
| Current Ratio(x) | 3.25 | 2.55 | 1.60 | 1.48 | 1.46 |
| Quick Ratio(x) | 2.56 | 1.78 | 1.08 | 0.91 | 0.90 |
| Interest Cover(x) | 5.06 | 10.98 | 0.11 | 4.25 | -10.60 |
| Total Debt/Mcap(x) | 0.01 | - | - | - | - |
Compare Financial Ratios of peers of AKUMS DRUGS & PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| AKUMS DRUGS & PHARMACEUTICALS | ₹9,856.4 Cr | 0.3% | 16% | 9.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹456,989.0 Cr | 1.7% | 6.4% | 12.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹179,471.0 Cr | 3% | 2.8% | 0.9% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹161,290.0 Cr | 2.3% | 9.1% | 44.6% | Stock Analytics | |
| CIPLA | ₹117,820.0 Cr | 0.3% | 6.1% | -3.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹114,730.0 Cr | -0.1% | 8.9% | 1.9% | Stock Analytics | |
AKUMS DRUGS & PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| AKUMS DRUGS & PHARMACEUTICALS | 0.3% |
16% |
9.2% |
| SENSEX | 0.9% |
4.2% |
-6% |
You may also like the below Video Courses
